# AstraZeneca Pharma India (NSE: ASTRAZEN) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ASTRAZEN · Pivot · prices to 21 Oct 2026

AstraZeneca Pharma India (NSE: ASTRAZEN) closed at ₹6,026.00 on 21 Oct 2026, down 0.30% on the day. With a market capitalisation of ₹15,139 Cr, it ranks 425th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 80.9× trailing earnings, against a return on equity of 15.0% in FY25. Over the past year the share price has fallen 34.3%. Its 52-week range is ₹5,640.00 (9 Oct 2026) to ₹9,849.50 (3 Nov 2025); the last close is 38.8% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹579 Cr (+20.4% year on year) and net profit ₹45 Cr (−23.0%), on a standalone basis. Promoters held 75.00% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹6,026.00 |
| Market cap | ₹15,139 Cr |
| P/E (trailing) | 80.9 |
| ROE | 15.0% (FY25) |
| ROCE | 31.2% (FY25) |
| Debt to equity | 0 |
| 52-week high | ₹9,849.50 (3 Nov 2025) |
| 52-week low | ₹5,640.00 (9 Oct 2026) |
| 1-year return | −34.3% |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹579 Cr | +20.4% | ₹45 Cr | −23.0% | ₹17.95 |
| Q3 FY26 | ₹612 Cr | +38.9% | ₹33 Cr | +5.6% | ₹13.04 |
| Q2 FY26 | ₹559 Cr | +37.0% | ₹54 Cr | +41.1% | ₹21.69 |
| Q1 FY26 | ₹526 Cr | +35.8% | ₹56 Cr | — | ₹22.33 |
| Q4 FY25 | ₹480 Cr | +25.4% | ₹58 Cr | +47.5% | ₹23.30 |
| Q3 FY25 | ₹440 Cr | +44.0% | ₹31 Cr | +95.3% | ₹12.34 |
| Q2 FY25 | ₹408 Cr | +31.2% | ₹38 Cr | −26.6% | ₹15.37 |
| Q1 FY25 | ₹388 Cr | +31.2% | −₹12 Cr | −121.9% | −₹4.72 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,716 Cr | ₹116 Cr |
| FY24 | ₹1,296 Cr | ₹162 Cr |
| FY23 | ₹1,003 Cr | ₹99 Cr |
| FY22 | ₹806 Cr | ₹62 Cr |
| FY21 | ₹814 Cr | ₹93 Cr |
| FY20 | ₹832 Cr | ₹72 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 75.00%
- Foreign institutions: 2.68%
- Domestic institutions: 6.08%
- Non-institutions: 16.24%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Syngene International](https://app.pivotnow.in/stock/SYNGENE) | ₹389.35 | ₹15,717 Cr | 49.4 | 6.5% |
| [Eris Lifesciences](https://app.pivotnow.in/stock/ERIS) | ₹1,129.50 | ₹15,652 Cr | 24.9 | 15.9% |
| [Alembic Pharmaceuticals](https://app.pivotnow.in/stock/APLLTD) | ₹785.00 | ₹15,430 Cr | 22.9 | 11.2% |
| [Alivus Life Sciences](https://app.pivotnow.in/stock/ALIVUS) | ₹1,252.00 | ₹15,367 Cr | 27.3 | 17.2% |
| [Poly Medicure](https://app.pivotnow.in/stock/POLYMED) | ₹1,502.40 | ₹15,228 Cr | 47.4 | 10.4% |
| [Jubilant Pharmova](https://app.pivotnow.in/stock/JUBLPHARMA) | ₹922.00 | ₹14,686 Cr | 36.7 | 13.4% |

## Questions and answers

### What is the share price of AstraZeneca Pharma India today?

AstraZeneca Pharma India (NSE: ASTRAZEN) last closed at ₹6,026.00 on 21 Oct 2026. Its 52-week high is ₹9,849.50 and its 52-week low is ₹5,640.00.

### What is the market cap of AstraZeneca Pharma India?

AstraZeneca Pharma India's market capitalisation is ₹15,139 Cr (₹15,139 Cr) at the 21 Oct 2026 close, ranking 425th among the NSE companies Pivot tracks.

### What is the P/E ratio of AstraZeneca Pharma India?

AstraZeneca Pharma India trades at a trailing P/E of 80.9. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 36.7.

### What is the ROE and ROCE of AstraZeneca Pharma India?

Return on equity was 15.0% in FY25 and return on capital employed was 31.2% in FY25 (standalone figures).

### Is AstraZeneca Pharma India a debt-free company?

AstraZeneca Pharma India is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were AstraZeneca Pharma India's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), AstraZeneca Pharma India reported revenue of ₹579 Cr, +20.4% year on year, and net profit of ₹45 Cr, −23.0% year on year.

### How has AstraZeneca Pharma India stock performed over the last year?

AstraZeneca Pharma India's share price has fallen 34.3% over the past year, −25.1% over three months and −9.9% over one month, to the 21 Oct 2026 close.

### What is the shareholding pattern of AstraZeneca Pharma India?

As of 30 Jun 2026: promoters 75.00%, foreign institutions 2.68%, domestic institutions 6.08%, non-institutions 16.24%.

### Who are AstraZeneca Pharma India's competitors?

The listed Pharma & Healthcare companies closest to AstraZeneca Pharma India by market cap are Syngene International, Eris Lifesciences, Alembic Pharmaceuticals, Alivus Life Sciences, Poly Medicure and Jubilant Pharmova.

### Is AstraZeneca Pharma India a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out AstraZeneca Pharma India's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ASTRAZEN against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.